Header Logo

Connection

Jahangir Alam to Anti-Bacterial Agents

This is a "connection" page, showing publications Jahangir Alam has written about Anti-Bacterial Agents.
Connection Strength

1.437
  1. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
    View in: PubMed
    Score: 0.192
  2. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores. Anaerobe. 2021 Jun; 69:102352.
    View in: PubMed
    Score: 0.147
  3. Accelerate PhenoTestTM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. Ann Pharmacother. 2018 08; 52(8):754-762.
    View in: PubMed
    Score: 0.120
  4. A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment. J Vis Exp. 2017 05 25; (123).
    View in: PubMed
    Score: 0.113
  5. Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
    View in: PubMed
    Score: 0.110
  6. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
    View in: PubMed
    Score: 0.106
  7. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe. 2016 Aug; 40:10-4.
    View in: PubMed
    Score: 0.105
  8. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
    View in: PubMed
    Score: 0.105
  9. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May; 71(5):1245-51.
    View in: PubMed
    Score: 0.104
  10. Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Aug; 56(8):4360-4.
    View in: PubMed
    Score: 0.080
  11. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
    View in: PubMed
    Score: 0.045
  12. The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
    View in: PubMed
    Score: 0.043
  13. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
    View in: PubMed
    Score: 0.037
  14. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
    View in: PubMed
    Score: 0.036
  15. In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrob Agents Chemother. 2020 07 22; 64(8).
    View in: PubMed
    Score: 0.035
  16. Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
    View in: PubMed
    Score: 0.031
  17. Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.